source: Thyroid

year: 2022

authors: Henry B. Burch, Petros Perros, Tomasz Bednarczuk, David S. Cooper, Peter J. Dolman, Angela M. Leung, Ilse Mombaerts, Mario Salvi, Marius N. Stan

Thyroid eye disease (TED) remains challenging for clinicians to evaluate and manage. Novel therapies have recently emerged, and their specific roles are still being determined. Most patients with TED develop eye manifestations while being treated for hyperthyroidism and under the care of endocrinologists. Endocrinologists, therefore, have a key role in diagnosis, initial management, and selection of patients who require referral to specialist care. Given that the need for guidance to endocrinologists charged with meeting the needs of patients with TED transcends national borders, and to maximize an international exchange of knowledge and practices, the American Thyroid Association and European Thyroid Association joined forces to produce this consensus statement.

Reducing morbidity and improving the quality of life in patients with TED is important to consider. Measures to reduce morbidity associated with TED and improve patients’ QoL include early identification and management of thyroid dysfunction, smoking cessation, adequate control of thyroid hormone levels, prompt management of active TED, and referral to an ophthalmologist with experience in TED for assessment and management of the orbital disease.

Share

Discuss in Social Wall

Twitter

Share to rareTeam

myBinder